Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 399

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 399
---
 result, for the quarterly periods ended March 31, 2025 and June 30, 2025, respectively, the Notes were, and for the quarterly period ending September 30, 2025, the Notes are, convertible at the option of the holders of the Notes. During the three and six months ended June 30, 2025 and through the date of this filing, the amount of the principal balance of the Notes that has been converted was not material.The Company incurred $10.9 million of transaction costs related to the issuance of the Notes, which are being amortized to interest expense over the term of the Notes using the effective interest method. As of June 30, 2025, the remaining amortization period of the debt discount was approximately 3.8 years and the effective interest on the Notes was 4.6%. The following table sets forth interest expense recognized related to the Notes (in thousands):Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Coupon interest expense$3,162 $3,162 $6,325 $6,325 Amortization of debt discount and issuance costs427 407 860 821 Total interest expense on convertible notes$3,589 $3,569 $7,185 $7,146 As of June 30, 2025 and December 31, 2024, the estimated fair value of the Notes was $561.6 million and $481.9 million, respectively. The fair values were determined based on the quoted price of the convertible notes in an inactive market on the last trading day of the reporting period and have been classified as Level 2 in the fair value hierarchy.

10. Stockholders’ Equity

Common StockOn September 9, 2022, the Company filed an automatic shelf registration statement on Form S-3 with the SEC (the “2022 Shelf Registration”), which became effective upon filing, pursuant to which the Company registered for sale from time to time in one or more offerings an unlimited amount of any combination of the Company’s common stock, preferred stock, debt securities and warrants, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. This automatic shelf registration statement will remain in effect for up to three years from the date it became effective. As of June 30, 2025, the Company had not issued any securities pursuant to the automatic shelf registration statement.On